|
|
||||||||
| ABSTRACT |
|
|
|---|
| INTRODUCTION |
|
|
|---|
Chronic Chagas heart disease (cChHD) evolves gradually from an asymptomatic period with radiographic or electrocardiographic manifestations known as the indeterminate phase, and progresses slowly to a dilated cardiomyopathy manifested by arrhythmias, left ventricular dysfunction, embolic episodes, and autonomic dysfunction.2,3 The apical aneurysm is found to be a distinctive pathologic marker in more than 50% of symptomatic patients.4
In general, the cause of death is heart failure or thromboembolic phenomena. Anatomically, the heart of a patient with cChHD is characterized by myocardial damage associated with mononuclear inflammatory foci scattered throughout the organ.2,4 The coexistence of areas of myocytic degeneration, inflammatory infiltration, and fibrosis suggests a chronically evolving process. The lesions are progressive, self-perpetuating, and cumulative.
Since the intracellular forms of the parasite (Trypanosoma cruzi) that cause this disease are rarely found at the sites of the heart lesions, the hypothesis of an autoimmune process has been proposed as a leading mechanism of cChHD pathogenesis.5,6 However, polymerase chain reaction (PCR) amplification and immunohistochemical techniques showed the presence of parasite DNA and proteins close to the inflammatory foci in lesions found in cardiac and digestive tissue from patients infected in endemic areas in Brazil and Venezuela.611
In this study, we applied the PCR technique to analyze the proportion of sections containing parasite DNA in left ventricular free walls or cardiac apexes collected from heart necropsies or explants in cChHD patients from Argentina who died at different stages of heart disease progression. The combination of clinical, electrocardiographic, histologic and PCR-based analysis enabled us to demonstrate a significant association between the detection of parasite DNA with inflammation, fibrosis, and clinical progression of cChHD.
| MATERIALS AND METHODS |
|
|
|---|
On admission, cChHD patients were clinically classified according to the criteria of Kuschnir into four groups: 0 (positive serology only), I (abnormal electrocardiogram [ECG], II (radiologic heart enlargement), and III (overt signs of heart failure).12 At the time of death or heart transplantation the patients were reclassified based on the progression of the cardiomyopathy. Such progression was determined according to 1) development of new electrocardiographic changes (NEC): right bundle branch block (RBBB), left anterior fascicular block (LAFB), RBBB plus LAFB, left bundle branch block (LBBB), complete atrial ventricular block (CAVB), atrial fibrillation (AF), atrial flutter (AA), atrial tachycardia, and sustained ventricular tachycardia (SVT); and 2) deterioration of the clinical group.
The cChHD patients included in this study did not receive trypanocidal therapy. Patients undergoing heart transplantation did not receive trypanocidal prophylaxis. Their clinical and ECG conditions are shown in Table 1
.
|
|
To compare the number of MNC/HPF and the volume fraction of the fibrosis between patient groups, we analyzed one section of the left ventricular free wall region from each heart. In cases where two sections of the left ventricular free wall were previously selected, we analyzed the one with the highest degree of inflammation.
Polymerase chain reaction. Two to five 10 µm-thick serial tissue specimens consecutive to the section stained for histologic analysis were transferred into sterile polypropylene microtubes (Eppendorf AF, Hamburg, Germany) for isolation of DNA. To avoid cross-contamination between samples, sterile disposable instruments and gloves were used during handling. The DNA was extracted using the QiAmp tissue kit (Qiagen, Valencia, CA) following the manufacturers recommendations for paraffin-embedded tissues, as previously reported.16 Because the tissues were obtained from archival specimens, some of them from necropsies collected more than 10 years ago, the integrity of the purified DNA was firstly verified by the amplification of a human ß-globin gene fragment, as reported previously.17 Accordingly, we searched for T. cruzi DNA only in those samples that were found to be positive by a ß-globin gene-based PCR.
A hot-start PCR procedure targeted to the 330-basepair minicircle fragment of the T. cruzi kinetoplast genome was performed in 50-µL reactions using PCR tubes containing wax beads (Molecular BioProducts, Inc., San Diego, CA). The 12-µL lower mixture carried 2 µL of 25 mM MgCl2, 5 µL of 2.5 mM of each deoxynucleotide triphosphate (Promega, Madison, WI), 1.5 µL of 50 µM of primers 121 (5'-AAATAATGTACGGG(T/G)GAGATGCATGA-3') and 122 (5'-GGTTCGATTGGGGTT GGTGTAATATA-3'), and 1.2 µL of 10x Taq buffer (Gibco-BRL, Gaithersburg, MD). The 33-µL upper mixture contained 4 µL of 25 mM MgCl2, 3.3 µL of 10x Taq buffer, 1.25 units of Taq DNA polymerase (Gibco-BRL), and 5 µL of specimen DNA. Amplification was performed in a MJR PTC-100 thermocycler (MJ Research, Inc., Waltham, MA) under the conditions previously reported.18 The PCR products were analyzed by 3% agarose gel electrophoresis followed by Southern hybridization, as previously reported.18 The results obtained by the kinetoplast DNA (kDNA)-PCR on the serial tissue specimens consecutive to the histologic heart section were scored as 1 if at least one of them amplified T. cruzi kDNA or as 0 if all the tested specimens were PCR negative (Table 2
).
In addition, a nested PCR procedure targeted to the 435-basepair short interspersed repetitive element (SIRE)19 of the nuclear genome of T. cruzi was assayed in the heart sections obtained from two group B patients (cases 9 and 12, Table 1
). The first round of the SIRE PCR was carried out in a 50-µL volume reaction containing 15 pm of primers Sis (5'-GGAGAGCTGGCTAACTTAAT-3') and SIa (5'-GGGGTCCTCCAACCACAAGAC-3') using the following cycling conditions: one cycle at 94°C for five minutes and 58°C for two minutes, followed by 35 cycles at 72°C for one minute, 94°C for one minute, and 58°C for one minute, and a final step at 72°C for seven minutes. The second round of SIRE PCR was carried out in a 50-µL volume reaction with 15 pm of primers SIns (5'-GTATGAATCTTTTGGGAAGAAC-3') and SIna (5'-TTACTTACGAAGTGGCAGACT-3') using the following cycling conditions: one cycle at 94°C for five minutes and 55°C for two minutes, followed by 35 cycles at 72°C for one minute, 94°C for one minute, and 55°C for one minute, and a final step at 72°C for 10 minutes. The SIRE PCR products were visualized by UV light after electrophoresis in ethidium bromide-stained 3% agarose gels.
Negative controls for each PCR consisted of specimen preparation reagents without DNA. Positive specimen controls consisted of 10-µm serial brain tissue specimens obtained from a necropsy of a patient with acquired immuno-deficiency syndrome who died of chagasic meningoencephalitis. Purification of DNA from tissue specimens, assembling of reagent mixtures, cycling, gel electrophoresis, and hybridization procedures were carried out in different laboratory working areas. The PCR was carried out blinded to the clinical and/or the histologic findings.
Statistical analysis. Continuous variables were analyzed by one-way analysis of variance (ANOVA) and unpaired t-tests when appropriate. Categorical variables were compared by the chi-square test and Fishers exact test. The number of inflammatory cells and the area of fibrosis in the histologic heart sections were expressed as median values. The agreement between inflammation and fibrosis was studied using the Spearman correlation coefficient. The Kruskal-Wallis one-way ANOVA was used to test the differences between groups. The Mann-Whitney U test was used to evaluate the agreement between the median value of inflammatory cell counts and the median percentage of fibrosis with the PCR scores in each heart tissue block. P values < 0.05 were considered statistically significant. The pathologic and clinical data were analyzed using the SPSS® 6.1 statistical analysis software for Windows (SPSS, Inc., Chicago, IL).
| RESULTS |
|
|
|---|
Group B were composed of 10 cChHD patients, five males and five females, with a mean ± SD age of 50.60 ± 14.37 years, with evidence of HF as cause of death or indication for heart transplantation. The mean ± SD time of follow-up was 968.6 ± 925.8 days and the mean ± duration of the clinical symptoms of heart failure was 17.80 ± 9.55 months (Table 1
).
Group C was composed of six patients with DCM, four males and two females, with a mean ± SD age of 47.50 ± 13.68 years, with HF at the moment of death or heart transplantation. The mean ± SD time of follow-up was 426.67 ± 319.2 days and the mean ± SD duration of the clinical symptoms of heart failure was 25.67 ± 17.47 months (Table 1
). The mean ages, time of follow-up, and period with heart failure were similar among groups B and C (Table 1
).
During monitoring of the cChHD patients, new electrocardiographic changes (NECs) were detected in two of six cases in group A and in all patients in group B (P = 0.008). Conversely, an NEC occurred only in one of six cases in control group C, a significant difference when compared with the NECs found in group B (P = 0.001). No deterioration of the clinical group was detected in group A; however, a clinical deterioration occurred in 3 of 10 patients in group B (P not significant). The causes of death or heart transplantation for all patients are shown in Table 1
.
Histopathologic findings.
The mean ± SD heart weight was 467.5 ± 170.0 grams, 490.5 ± 114.7 grams, and 587.5 ± 200.0 grams in groups A, B, and C respectively (P not significant) (Table 2
). We observed borderline myocarditis in three of 16 hearts and active myocarditis in 12 of 16 hearts from cChHD patients. In contrast, only two of six DCM hearts presented borderline myocarditis and none had active myocarditis (Table 2
). The morphometric data for inflammation and fibrosis are shown in Table 2
. There was a positive correlation between the inflammation and fibrosis measured in the histologic heart sections of patients with Chagas disease (Spearman correlation coefficient = 0.388, P < 0.001).
A comparison between the median intensity of heart tissue inflammation and the percentage of fibrosis, as measured in the left ventricular free wall sections of the hearts from groups A, B, and C is shown in Figure 1
. The median number of MNC/HPF in left ventricular wall specimens in group A (11, range = 1116) was significantly lower than in group B (31, range = 1753) (P = 0.039) (Figure 1A
). The percentage of fibrosis in the same left ventricular wall sections was 15.5% (range = 618%) in group A and 20.5% (range = 1530%) in Group B (P not significant) (Figure 1B
). The comparison of inflammation between sections from groups B and C showed significant differences; we observed a median value of 31 (range = 1753) MNC/HPF in group B compared with 7 (range = 611) MNC/HPF in group C (P = 0.005) (Figure 1A
). The percentage of fibrosis in group C was 10.5% (range = 912%), which was significantly lower than that measured in group B (P = 0.005) (Figure 1B
). No significant differences in inflammation and fibrosis were observed between groups A and C (Figure 1A and B
).
|
The appearance of NECs in all patients (groups A, B, and C) correlated with inflammatory infiltration in the LV wall samples (Spearman correlation coefficient = 0.578, P < 0.01), as well as with the percentage of fibrosis (
= 0.620, P < 0.005).
Detection of T. cruzi DNA by PCR.
We tested for the presence of T. cruzi DNA in serial tissue specimens consecutive to the section stained for morphometric analysis from each selected heart tissue block (sections a and b, Table 2
). One hundred nineteen specimens were processed for PCR analysis; 82 were positive for amplification of the human ß-globin gene (Table 2
) and were further analyzed by the kDNA-based PCR. Parasite kDNA amplicons were obtained from 53 (75.7%) of 70 tissue specimens tested (Table 2
) from 15 of the 16 hearts from patients with Chagas disease analyzed in this study. The only heart sections for which no parasite DNA could be amplified were those from case 1, a patient with positive serologic test results for Chagas disease but without clinical or histologic signs of myocarditis (Table 2
and Figure 2A
and lane 1). None of the 12 heart specimens from hearts of DCM patients were positive for T. cruzi kDNA (Table 2
).
|
Four PCR results from patients in group B are shown in Figure 2DH
. Patient 7 was a 48-year-old man admitted into clinical group I who had clinical deterioration and was reassigned to Kuschnirs group III (Table 1
). The histologic analysis of the heart tissue sections from the left ventricular free wall (Figure 2D
and Table 2
, histologic section 7b) showed evidence of active myocarditis; parasite kDNA was obtained from all the tested serial tissue specimens (Figure 2
, lane 4). Case 9 was a 54-year-old woman who was admitted into clinical group II, progressed to clinical group III, and died after a rapid onset of symptoms of HF. The histologic sections from her heart showed active myocarditis (Table 2
, histologic section 9b and Figure 2E
) with evidence of T. cruzi kDNA (Figure 2
, lane 5). Patient 14 died of heart failure at age 27 (Figure 2F
). In the left ventricular free wall from his heart necropsy, all tested serial samples were PCR positive (Table 2
, histologic sections 14a and 14b and Figure 2
, lane 6). Interestingly, amastigote nests were detected in another histologic section, adjacent to the ones analyzed by the PCR. Case 16 was a 46-year-old woman who underwent a heart transplant. Her explanted heart showed regions with very low counts of inflammatory cells (Figure 2G and H
); however, parasite DNA was found in specimens consecutive to the histologic section with myocarditis (Figure 2H
, lane 8). In Group C, parasite kDNA was not detected in any DCM control specimen, as shown in Figure 2I
, lane 9 (case C in Table 2
). The result of the kDNA PCR was negative for DNA samples extracted from archival specimens of brain, lung, kidney, and liver collected at necropsies from cases 3, 6, 14, and 16.
Six tissue sections positive for T. cruzi kDNA from patients 8, 9, 10, 11, 12, and 14 were further tested for the presence of the nuclear, multicopy SIRE.19 A nested PCR procedure resulted in the amplification of a 230-basepair SIRE fragment from two heart samples (cases 9 and 12, Table 2
). The amplicon from case 9 was sequenced and aligned with those from parasite strains CL-Brenner and Tulahuen II,19 as well as with SIRE sequences amplified from two endomyocardial biopsy specimens (Figure 3
).20
|
|
Parasite DNA was also linked with the degree of fibrosis found in the same tissue sections. It was detected in serial samples from two (33.3%) of six sections with mild fibrosis collected from hearts 1,2, 5, and 16, in 11 (78.6%) of 14 sections with moderate fibrosis collected from hearts 36, 10, 12, 13, and 16, and in all 10 sections (100%) with severe fibrosis collected from hearts 79, 11, 14, and 15) (P < 0.01) (Figure 4
).
Parasite DNA and apical aneurysm.
Heart sections from cardiac apexes of cases 1 and 2 of Group A (Kuschni
s Group 0) as well as cases 7 and 15 from Group B (Kuschnirs Group III) were tested by kDNA based PCR. In apical samples from Group A cases there were no evidences of parasite DNA, whereas in those from Group B cases the PCR results were positive (Table 2
).
Association of T. cruzi kDNA with cause of death or transplantation and disease progression.
The proportion of serial tissue specimens containing T. cruzi kDNA was 45% (10 of 22) in group A and 89.6% (43 of 48) in group B (P < 0.001) (Figure 5
). Furthermore, the PCR result was positive in 25% (3 of 12) of the heart specimens from Kuschnir groups 0 and I, in 70% (7 of 10) of the samples from group II, and in 90% (43 of 48) of the samples from Group III (P < 0.001) (Figure 5
). Moreover, parasite DNA was detected in all patients who showed clinical deterioration evolving to Kuschnirs group III (Table 2
).
|
| DISCUSSION |
|
|
|---|
The inflammation in cChHD hearts with HF (group B) was higher in the subepicardium and mesocardial layers, reflecting the fact that bloodstream parasites reach the heart from the coronary vessels, contacting the epicardium (Figure 1C
). The distribution of fibrosis in the myocardial layers of cChHD with HF followed the pattern of inflammation, which was clearly not the case for DCM. Indeed, heart sections from cChHD patients showed more fibrosis in the mesocardium, whereas in DCM patients the subendocardium seemed to be more involved (Figure 1D
), probably as a consequence of the disturbance of oxygen supply and demand.2527
The appearance of NECs during follow-up is a striking characteristic of cChHD.2 The progression of ECG abnormalities was reported to be approximately 2025% in longitudinal population studies of individuals chronically infected with T. cruzi for seven or more years.2830 In this study, NECs were detected in 100% of cases in group B, in 30% of cases from group A, and in only 17% in group C. Remarkably, in group B the ECG evolution was associated with heart failure and death, with heart tissue necropsies showing diffuse and fibrosing myocarditis, which are typical signs of end-stage cChHD that all linked to the detection of parasite DNA.
The paucity of parasite nests in hearts of cChHD patients led several investigators to discard a role for the parasite in its pathogenesis.6,17,31 In certain series of necropsies, amastigote nests were identified in only 2536% of the hearts.21,32,33 However, immunohistochemical analysis using monoclonal antibodies to T. cruzi allowed detection of T. cruzi antigens in 71% of the cardiac regions with moderate or severe myocarditis and in only 16.6% with mild or absent myocarditis.7 Moreover, a significant correlation between the presence of parasite antigens and increased CD8 T cell counts has been also reported.34
The PCR has shown the presence of nuclear and kinetoplastid sequences from the parasite in biopsy or necropsy specimens from hearts and digestive tissues of patients with chronic Chagas disease from endemic regions of Brazil and Venezuela.811 In the present study, amastigote nests were detected in only one heart tissue block (case 14 in group B), whereas the PCR amplified the highly repetitive kinetoplastid minicircle sequence in 15 of 16 heart necropsy specimens (Table 2
). For the first time, the middle repetitive nuclear element known as SIRE19 has been amplified from an eight-year-old heart preparation and sequenced (Figure 3
). The characterization of T. cruzi nuclear DNA sequences from these archival necropsy specimens, as well as those from heart biopsy specimens,20 provide a starting point to determine the genomic structure of the parasite populations associated with the human tissue lesions.
Our study suggests that there is a strong association between the histologic evidence of heart tissue damage and T. cruzi amplicons. Indeed, there was a significant correlation between the number of tissue sections positive by PCR and the intensity of heart inflammation, as well as fibrosis at the corresponding cardiac lesions (Figure 4
). The proportion of PCR-positive sections increased in patients who died or received a heart transplant due to HF (group B) compared with those from patients who had died of other causes (group A) (Figure 5
). This finding suggests that the transition from a chronic asymptomatic period of the disease, represented by infected individuals with the clinical profile of group A patients, to manifest cChHD, the clinical profile of group B patients, is directly associated with the detection of parasite DNA in the affected tissues. Moreover, amplification of specific parasite DNA sequences was linked to clinical deterioration (Figure 5
).
The absence of intact parasites at the sites of inflammation suggests that microorganisms invading the myocardium are rapidly destroyed, probably immunologically, whereas DNA and antigens may be still detected at the sites of injury. Based on experimental evidence showing that parasite DNA did not persist for more than two days in murine-infected tissues,35 PCR findings appear to indicate intact or recently destroyed parasites, rather than mere residual DNA.
The positive correlation between parasite DNA in tissue lesions and inflammation, fibrosis, and disease progression and severity suggests that during the chronic infection the parasite contacts the heart at different times and locations, invoking an immunologic response at these sites. As a direct consequence, parasites are lysed, the surrounding tissue is damaged, and replacement fibrosis ensues. The accumulation of these multifocal lesions, mainly in the left ventricular wall, leads to cardiac dysfunction. Moreover, heart damage may be also enhanced by the humoral immune response of the patient against intracellular parasite antigens, such as the T. cruzi ribosomal P proteins, which generates arrhythmogenic antibodies.36,37
In conclusion, these results suggest not only a relevant role of the parasite in the pathogenesis and disease progression of cChHD, but also a need to develop novel anti-parasitic drugs, with sufficient efficacy to clear intracellular parasites, thus preventing the progression of heart disease.38,39
Received August 1, 2003. Accepted for publication October 22, 2003.
Acknowledgments: We are grateful to Dr. Rubén Laguens (Division de Anatomía Patológica, Instituto de Cardiología y Cirugía Cardiovascular, Fundación Favaloro, Buenos Aires, Argentina) and Dr. Felipe Kierszenbaum (Department of Microbiology, Michigan State University, East Lansing, MI) for their helpful comments on the manuscript, and to Sonia Lafon and Julia Ferrando for their skillful technical assistance.
Financial support: This work was supported by grants from the World Health Organization-Tropical Diseases Research projects, the Regional Technical Cooperation project RLA 6-0-26 and Coordinated Research Project of the International Atomic Energy Agency, Consejo Nacional de Ciencia y Tecnologia (PEI 107/97), the University of Buenos Aires, FONCyT BID 802/OC-AR PICT 01421 and PI CT 02030, the Alberto Roemmers and Bunge and Born Foundations, and Ramon Carrillo-Arturo Oñativia of the Secretary of Health of Argentina. The work of Matiano J. Levin was partially supported by an International Research Scholar grant from the Howard Hughes Medical Institute (Chevy Chase, MD).
Authors addresses: Alejandro G. Schijman, Juan M. Burgos, Silvia Brandariz, and Mariano J. Levin, Vuelta de Obligado 2490, Second Floor, (CP 1428), Buenos Aires, Argentina, Telephone: 54-11-4783-2871, Fax: 54-11-4786-8578, E-mail: MLevin{at}dna.uba.ar. Carlos A. Vigliano, División Patología. Instituto de Cardiología y Cirugía Cardiovascular, Fundación Favaloro, Belgrano 1746 (CP 1093), Buenos Aires, Argentina, Telephone and fax : 54-11-4378-1315 and Departamento de Cardiología, Hospital Eva Perón, Ruta 8 y Diego Pombo, San Martín, Provincia de Buenos Aires, Buenos Aires, Argentina 005411-3781315. Rodofo J. Viotti, Bruno E. Lococo, María I. Leze, and Héctor A. Armenti, Departamento de Cardiología, Hospital Eva Perón, Ruta 8 y Diego Pombo, San Martín, Provincia de Buenos Aires, Buenos Aires, Argentina 005411-3781315.
| REFERENCES |
|
|
|---|
This article has been cited by other articles:
![]() |
D. F. Hoft, C. S. Eickhoff, O. K. Giddings, J. R. C. Vasconcelos, and M. M. Rodrigues Trans-Sialidase Recombinant Protein Mixed with CpG Motif-Containing Oligodeoxynucleotide Induces Protective Mucosal and Systemic Trypanosoma cruzi Immunity Involving CD8+ CTL and B Cell-Mediated Cross-Priming J. Immunol., November 15, 2007; 179(10): 6889 - 6900. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Hyland, J. S. Leon, M. D. Daniels, N. Giafis, L. M. Woods, T. J. Bahk, K. Wang, and D. M. Engman Modulation of Autoimmunity by Treatment of an Infectious Disease Infect. Immun., July 1, 2007; 75(7): 3641 - 3650. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. K. Giddings, C. S. Eickhoff, T. J. Smith, L. A. Bryant, and D. F. Hoft Anatomical Route of Invasion and Protective Mucosal Immunity in Trypanosoma cruzi Conjunctival Infection. Infect. Immun., October 1, 2006; 74(10): 5549 - 5560. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. FLORES-CHAVEZ, M.-F. BOSSENO, B. BASTRENTA, J.-L. A. DALENZ, M. HONTEBEYRIE, S. REVOLLO, and S. F. BRENIERE POLYMERASE CHAIN REACTION DETECTION AND SEROLOGIC FOLLOW-UP AFTER TREATMENT WITH BENZNIDAZOLE IN BOLIVIAN CHILDREN INFECTED WITH A NATURAL MIXTURE OF TRYPANOSOMA CRUZI I AND II. Am J Trop Med Hyg, September 1, 2006; 75(3): 497 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Viotti, C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment: A Nonrandomized Trial Ann Intern Med, May 16, 2006; 144(10): 724 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Petersen, K. A. Krumholz, J. Carmen, A. P. Sinai, and B. A. Burleigh Trypanosoma cruzi Infection and Nuclear Factor Kappa B Activation Prevent Apoptosis in Cardiac Cells Infect. Immun., March 1, 2006; 74(3): 1580 - 1587. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |